Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Urinary Symptom Profile in Early Multiple System Atrophy
Neuromuscular and Clinical Neurophysiology (EMG)
P9 - Poster Session 9 (5:30 PM-6:30 PM)
4-002
MSA is a rapidly progressive neurodegenerative disease that presents with motor and autonomic symptoms. Urinary symptoms can occur at any time along the disease process; however, no study has characterized patient reported urinary symptoms in MSA. The Urinary Symptom Profile (USP) is a validated, patient-reported assessment for stress urinary incontinence (SUI), overactive bladder (OAB), and low stream (LS). We applied this scale to a cohort of early MSA patients from the bioMUSE Natural history study.
Evaluate the Urinary Symptom Profile (USP) in patients with multiple system atrophy (MSA).
16 participants, (8 females), mean age 62 (range 49-79), mean duration of motor symptoms of 3 years, completed the Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, the Natural History and Neuroprotection in Parkinson Plus Syndromes-Parkinson Plus scale (PPS), and the Urinary Symptom Profile (USP) questionnaire. The PPS and UMSARS total urinary symptom scores were correlated with the total USP score using a t-distribution and the Spearman’s rank correlation.
The mean USP score was 14.06, (4-30). One participant had a bladder stimulator and 3 were taking medications for urinary symptoms. Total USP scores positively correlated with total urinary symptom scores from the UMSARS (p = 0.075, r2 = 0.458) and PPS (p = 0.002, r2 = 0.713). Across this cohort, the most severe complaints were related to urinary urgency (OAB avg = 8.4), and reduced amount of time to hold urine (SUI avg = 2.63). Subscale analysis indicates the most common symptoms relate to OAB, and least common were SUI.
In early MSA, urinary symptoms are greatest in relation to overactive bladder, specifically urgency and frequency. These results suggest that the USP can be used for comprehensive evaluation of urinary complaints and give important insights to the concerns of patients early in disease.
Authors/Disclosures
Jessie Iregui
PRESENTER
Miss Iregui has nothing to disclose.
Amy Wynn, NP (Vanderbilt University Medical Center) Ms. Wynn has nothing to disclose.
Kaitlyn Rose Hay, Other (Vanderbilt University Medical Center) Miss Hay has nothing to disclose.
Cynthia Wong Cynthia Wong has received personal compensation for serving as an employee of Alterity Therapeutics.
David A. Stamler, MD (Alterity Therapeutics) Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics.
Daniel O. Claassen, MD, FAAN (Vanderbilt University Medical Center) Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark . The institution of Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Neuroscience. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for HD Insights. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from Griffin Family Foundation. The institution of Dr. Claassen has received research support from Neurocrine. The institution of Dr. Claassen has received research support from Vaccinex. The institution of Dr. Claassen has received research support from AbbVie. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from Genentech/ Roche. The institution of Dr. Claassen has received research support from Prilenia. The institution of Dr. Claassen has received research support from Neurocrine/ HSG.